Compositions Comprising Fluorophore-Labeled UPAR-Targeting Peptide Conjugates
The formulation of fluorophore-labeled uPAR-targeting peptide conjugates with low water content, surfactants, and cryoprotectants addresses solubility and stability issues, enhancing their effectiveness in cancer diagnosis and treatment by ensuring complete solubilization and high stability, and achieving a favorable pharmacokinetic profile for tumor detection.
Patent Information
- Application Number
- JP2025197874
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-01-17
- Filing Date
- 2025-11-19
- Publication Date
- 2026-03-04
AI Technical Summary
Existing fluorophore-labeled uPAR-targeting peptide conjugates face issues with solubility and stability, particularly in compositions with low water content, which affect their effectiveness in diagnostic and therapeutic applications.
The compositions include a formulation with low water content, typically less than 5% by weight, incorporating a surfactant and cryoprotectant to enhance solubilization and stability, along with specific buffer systems, ensuring complete solubilization and high stability of the fluorophore-labeled receptor-targeting peptide conjugates.
The formulation achieves complete solubilization and high stability of the conjugates, enabling optimal surgical removal of tumors by providing a favorable pharmacokinetic profile with a high tumor-to-background ratio (TBR) and selective binding to uPAR receptors, facilitating effective cancer diagnosis and treatment.
Smart Images
Figure 2026035653000001_ABST